A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified March 2026 by Celgene
Sponsor
Celgene
Information Provided by (Responsible Party)
Celgene
Clinicaltrials.gov Identifier
NCT05519085
Other Study ID Numbers:
CA057-001
First Submitted
August 24, 2022
First Posted
August 28, 2022
Last Update Posted
April 29, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Relapsed or Refractory Multiple Myeloma
Drug: mezigdomideDrug: Pomalidomide

Study Design

Study TypeInterventional
Actual Enrollment810 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Study Start DateSeptember 19, 2022
Actual Primary Completion Date7mos 3w from now
Actual Study Completion Date7yrs 6mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
MeziVd (mezigdomide, bortezomib and dexamethasone)
Drug: mezigdomide
Specified dose on specified days
PVd (pomalidomide, bortezomib and dexamethasone)
Drug: Pomalidomide
Specified dose on specified days

Outcome Measures

Primary Outcome Measures
  1. Progression-free Survival (PFS)
Secondary Outcome Measures
  1. Recommended mezigdomide dose
    Stage 1 only
  2. Plasma concentrations of mezigdomide
    Stage 1 only
  3. Overall Survival (OS)
  4. Overall Response (OR)
    OR is defined as the number of participants who achieve best response of partial response (PR) or better according to the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma
  5. Complete Response (CR) or better
    Defined as the number of participants who achieve best response of complete response (CR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
  6. Very Good Partial Response (VGPR) or better
    Defined as the number of participants who achieve best response of very good partial response (VGPR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
  7. Time to Response (TTR)
  8. Duration of Response (DOR)
  9. Time to Progression (TTP)
  10. Time to Next Treatment (TTNT)
  11. Progression-free Survival 2 (PFS-2)
  12. Minimal Residual Disease (MRD) negativity
    Defined as the number of participants who achieve complete response (CR) or better and MRD negativity (defined as less than 1 in 10\^5 nucleated cells \[by next generation flow cytometry\] in bone marrow aspirate)
  13. Number of participants with Adverse Events (AEs)
  14. Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores
    The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.
  15. Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score
    The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Inclusion Criteria \- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:. i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or. ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP). iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
Participants received 1 to 3 prior lines of antimyeloma therapy.
Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy.
Exclusion Criteria
Inclusion Criteria \- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:. i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or. ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP). iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
Participants received 1 to 3 prior lines of antimyeloma therapy.
Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy. Exclusion Criteria \- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:. i) Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded. ii) Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded.
For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
Participant has had prior treatment with mezigdomide or pomalidomide.
Other protocol-defined Inclusion/Exclusion criteria apply.

Contacts and Locations

Sponsors and CollaboratorsCelgene
Locations
Local Institution - 0366 | Los Alamitos California, United States, 90720Local Institution - 0272 | San Diego California, United States, 92123Local Institution - 0273 | West Hollywood California, United States, 90069Local Institution - 0381 | Aurora Colorado, United States, 80045Local Institution - 0380 | Farmington Connecticut, United States, 06030Local Institution - 0208 | New Haven Connecticut, United States, 06510Local Institution - 0303 | Coral Springs Florida, United States, 33321Local Institution - 0403 | Fort Myers Florida, United States, 33901Local Institution - 0401 | St. Petersburg Florida, United States, 33701Local Institution - 0402 | West Palm Beach Florida, United States, 33401Local Institution - 0211 | Athens Georgia, United States, 30607Local Institution - 0048 | Marietta Georgia, United States, 30060Local Institution - 0330 | Garden City Kansas, United States, 67846Local Institution - 0080 | Westwood Kansas, United States, 66205Local Institution - 0358 | Baton Rouge Louisiana, United States, 70808Local Institution - 0255 | New Orleans Louisiana, United States, 70112Local Institution - 0385 | Shreveport Louisiana, United States, 71103Local Institution - 0357 | Baltimore Maryland, United States, 21215Local Institution - 0246 | Boston Massachusetts, United States, 02215Local Institution - 0271 | Ann Arbor Michigan, United States, 48109Local Institution - 0364 | Detroit Michigan, United States, 48202Local Institution - 0410 | Minneapolis Minnesota, United States, 55404Local Institution - 0088 | Hattiesburg Mississippi, United States, 39401Local Institution - 0242 | Jackson Mississippi, United States, 39213Local Institution - 0288 | East Brunswick New Jersey, United States, 08816Local Institution - 0363 | Ridgewood New Jersey, United States, 07450Local Institution - 0302 | Albuquerque New Mexico, United States, 87131Local Institution - 0245 | Buffalo New York, United States, 14215Local Institution - 0257 | Lake Success New York, United States, 11042Local Institution - 0373 | New Hyde Park New York, United States, 11042Local Institution - 0371 | New York New York, United States, 10028Local Institution - 0108 | Rochester New York, United States, 14621Local Institution - 0374 | Shirley New York, United States, 11967Local Institution - 0372 | The Bronx New York, United States, 10469Local Institution - 0274 | Williamsville New York, United States, 14221Local Institution - 0260 | Durham North Carolina, United States, 27710Local Institution - 0400 | Cincinnati Ohio, United States, 45242Local Institution - 0377 | Cleveland Ohio, United States, 44111Local Institution - 0076 | Cleveland Ohio, United States, 44195Local Institution - 0376 | Mayfield Heights Ohio, United States, 44124Local Institution - 0359 | Allentown Pennsylvania, United States, 18103Local Institution - 0264 | York Pennsylvania, United States, 17403Local Institution - 0223 | Germantown Tennessee, United States, 38138Local Institution - 0378 | Abilene Texas, United States, 79606Local Institution - 0275 | Houston Texas, United States, 77030Local Institution - 0267 | San Antonio Texas, United States, 78229Local Institution - 0409 | San Antonio Texas, United States, 78240Local Institution - 0207 | Salt Lake City Utah, United States, 84106Local Institution - 0297 | Fredericksburg Virginia, United States, 22408Local Institution - 0408 | Norfolk Virginia, United States, 23502Local Institution - 0399 | Roanoke Virginia, United States, 24014Local Institution - 0268 | Seattle Washington, United States, 98108Local Institution - 0293 | Seattle Washington, United States, 98109Local Institution - 0097 | Spokane Washington, United States, 99208Local Institution - 0411 | Vancouver Washington, United States, 98684Local Institution - 0220 | Madison Wisconsin, United States, 53792Local Institution - 0318 | Chivilcoy Buenos Aires, Argentina, 6620Local Institution - 0213 | Buenos Aires Buenos Aires F.D., Argentina, 1425Local Institution - 0249 | Córdoba Córdoba Province, Argentina, 5016Local Institution - 0239 | Viedma R, Argentina, R8500ACELocal Institution - 0200 | Rosario Santa Fe Province, Argentina, 2000Local Institution - 0248 | S3000epv Santa Fe Province, Argentina, 3000Local Institution - 0214 | Buenos Aires , Argentina, CP1280AEBLocal Institution - 0055 | Liverpool New South Wales, Australia, 2170Local Institution - 0004 | Waratah New South Wales, Australia, 2298Local Institution - 0017 | Wollongong New South Wales, Australia, 2500Local Institution - 0327 | Birtinya Queensland, Australia, 4575Local Institution - 0221 | Box Hill Victoria, Australia, 3128Local Institution - 0003 | Melbourne Victoria, Australia, 3004Local Institution - 0002 | Melbourne Victoria, Australia, 3065Local Institution - 0040 | Nedlands Western Australia, Australia, 6009Klinik Ottakring | Vienna State of Vienna, Austria, 1160Universitätsklinikum Krems | Krems , Austria, 3500LKH Hochsteiermark - Standort Leoben | Leoben , Austria, 8700Universitätsklinikum St. Pölten | Sankt Pölten , Austria, 3100Hanusch-Krankenhaus | Vienna , Austria, 1140Ziekenhuis Oost-Limburg, Campus St.-Jan | Genk Limburg, Belgium, 3600UZ Gent | Ghent Oost-Vlaanderen, Belgium, 9000AZ Nikolaas | Sint-Niklaas Oost-Vlaanderen, Belgium, B-9100ZNA Cadix | Antwerp , Belgium, 2030Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador | Salvador Estado de Bahia, Brazil, 40301-155Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa | Porto Alegre Rio Grande do Sul, Brazil, 90110-270Instituto Joinvilense de Hematologia e Oncologia | Joinville Santa Catarina, Brazil, 89202-050Hospital Amaral Carvalho | Jaú São Paulo, Brazil, 17210-080Americas Centro de Oncologia Integrado | Rio de Janeiro , Brazil, 22793080Clínica Médica São Germano S/S Ltda | São Paulo , Brazil, 04537-080Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein | São Paulo , Brazil, 05652-900Local Institution - 0225 | Greenfield Park Quebec, Canada, J4V 2H1Local Institution - 0174 | Montreal Quebec, Canada, H4J 1C5Local Institution - 0222 | Québec Quebec, Canada, G1J 1Z4Local Institution - 0329 | Santiago Santiago Metropolitan, Chile, 7580206Local Institution - 0387 | Santiago Santiago Metropolitan, Chile, 8420383Local Institution - 0332 | Viña del Mar Valparaiso, Chile, 0Local Institution - 0062 | Beijing Beijing Municipality, China, 100043Local Institution - 0165 | Beijing Beijing Municipality, China, 100043Local Institution - 0141 | Beijing Beijing Municipality, China, 100091Local Institution - 0144 | Chongqing Chongqing Municipality, China, 400016Local Institution - 0237 | Xiamen Fujian, China, 361003Local Institution - 0117 | Guangzhou Guangdong, China, 450008Local Institution - 0177 | Guangzhou Guangdong, China, 510060Local Institution - 0168 | Guangzhou Guangdong, China, 510080Local Institution - 0238 | Shenzhen Guangdong, China, 518039Local Institution - 0412 | Liuzhou Guangxi, China, 0Local Institution - 0240 | Nanning Guangxi, China, 530007Local Institution - 0254 | Shijiazhuang Hebei, China, 50000Local Institution - 0395 | Luoyang Henan, China, 471003Local Institution - 0113 | Zhengzhou Henan, China, 450003Local Institution - 0142 | Wuhan Hubei, China, 430022Local Institution - 0155 | Changsha Hunan, China, 410008Local Institution - 0147 | Changsha Hunan, China, 410013Local Institution - 0111 | Nanjing Jiangsu, China, 210000Local Institution - 0139 | Wuxi Jiangsu, China, 214023Local Institution - 0287 | Shenyang Liaoning, China, 110004Local Institution - 0148 | Xi'an Shaanxi, China, 710004Local Institution - 0110 | Xi'an Shaanxi, China, 710126Local Institution - 0169 | Qingdao Shandong, China, 266000Local Institution - 0114 | Shanghai Shanghai Municipality, China, 200030Local Institution - 0350 | Shanghai Shanghai Municipality, China, 200434Local Institution - 0164 | Taiyuan Shanxi, China, 030001Local Institution - 0356 | Deyang Sichuan, China, 618000Local Institution - 0119 | Tianjin Tianjin Municipality, China, 300060Local Institution - 0353 | Ürümqi Xinjiang, China, 830001Local Institution - 0202 | Kunming Yunnan, China, 650032Local Institution - 0151 | Hangzhou Zhejiang, China, 310003Local Institution - 0348 | Linhai Zhejiang, China, 317000Local Institution - 0112 | Ningbo Zhejiang, China, 315010Local Institution - 0149 | Wenzhou Zhejiang, China, 32500Local Institution - 0150 | Beijing , China, 100034Local Institution - 0176 | Taiyuan , China, 030032Local Institution - 0037 | Brno Brno-město, Czechia, 625 00Local Institution - 0383 | Prague Praha 10, Czechia, 100 34Local Institution - 0039 | Prague , Czechia, 12808Local Institution - 0256 | Kuopio Northern Savonia, Finland, 70210Local Institution - 0072 | Helsinki , Finland, 00029Institut de cancérologie Strasbourg Europe (ICANS) | Strasbourg Alsace, France, 67033CHU Bordeaux Haut-Leveque | Pessac Aquitaine, France, 33600Centre Leon Berard | Lyon Cedex08 Auvergne-Rhône-Alpes, France, 69373Hopital Claude Huriez - CHU de Lille | Lille Nord, France, 59000Centre Hospitalier Universitaire Estaing | Clermont-Ferrand , France, 63100Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren | Limoges , France, 87042Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu | Nantes , France, 44093Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire Carémeau | Nîmes , France, 30029Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau | Tours , France, 37032Hôpital Saint Antoine | Paris Île-de-France Region, France, 75571TUM Klinikum | München Bavaria, Germany, 81675Klinikum Traunstein | Traunstein Bavaria, Germany, 83278Medizinisches Versorgungszentrum | Weiden Bavaria, Germany, 92367Universitätsklinikum Marburg | Marburg Hesse, Germany, 35033Praxis Onkologie am Raschplatz | Hanover Lower Saxony, Germany, 30161Universitätsklinikum Bonn | Bonn North Rhine-Westphalia, Germany, 53127Marien Hospital Düsseldorf | Düsseldorf North Rhine-Westphalia, Germany, 40479Universitaetsklinikum Schleswig-Holstein Campus Kiel | Kiel Schleswig-Holstein, Germany, 24105Local Institution - 0396 | Erfurt Thuringia, Germany, 99085Universitätsklinikum Aachen | Aachen , Germany, 52074Sozialstiftung Bamberg | Bamberg , Germany, 96049Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf | Dresden , Germany, 01307Universitaetsklinikum Hamburg-Eppendorf | Hamburg , Germany, 20251Asklepios Altona | Hamburg , Germany, 22763Universitaetsklinikum Tuebingen | Tübingen , Germany, 72076Gemeinschaftspraxis Dres. med. Björn Schöttker & Dominik Pretscher | Würzburg , Germany, 97080Evangelismos General Hospital of Athens | Athens Attikí, Greece, 106 76Alexandra General Hospital of Athens | Athens Attikí, Greece, 115 28G. Papanikolaou General Hospital | Thessaloniki Thessaloníki, Greece, 570 10HCG Aastha Cancer Centre | Ahmedabad Gujarat, India, 380060Marengo Asia Hospitals Gurugram | Gurugram Haryana, India, 122011KLES Dr. Prabhakar Kore Hospital & M.R.C | Belagavi Karnataka, India, 590010Mumbai Oncocare Centre - Nanachowk | Mumbai Maharashtra, India, 400036Meenakshi Mission Hospital and Research Centre | Madurai Tamil Nadu, India, 625107Tata Memorial Centre - Homi Bhabha Cancer Hospital | Varanasi Uttar Pradesh, India, 221002Christian Medical College & Hospital | Ludhiana , India, 141008Jawaharlal Institute Of Postgraduate Medical Education And Research | Puducherry , India, 605006Local Institution - 0121 | Galway Connacht, Ireland, H91 YR71Local Institution - 0122 | Cork , Ireland, T12 E8YVLocal Institution - 0120 | Dublin , Ireland, D08 E9P6Local Institution - 0251 | Limerick , Ireland, V94 F858Meir Medical Center | Kfar Saba Central District, Israel, 4428164Sheba Medical Center | Ramat Gan Central District, Israel, 5262100Hadassah Medical Center - Do Not Use - Duplicate Facility | Jerusalem Jerusalem, Israel, 91220Rambam Health Care Campus | Haifa Northern District, Israel, 3109601Sourasky Medical Center | Tel Aviv Tall Abīb, Israel, 6423906Rabin Medical Center | Peatch Tikva , Israel, 49100IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" | Meldola Emilia-Romagna, Italy, 47014Azienda Ospedaliera Sant'Andrea | Rome Roma, Italy, 00189Policlinico "G. Rodolico" | Catania Sicily, Italy, 95123IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola | Bologna , Italy, 40138Fondazione IRCCS Policlinico San Matteo | Pavia , Italy, 27100National Cancer Center Hospital East | Kashiwa Chiba, Japan, 277-8577Japan Community Healthcare Organization Kyushu Hospital | Kitakyushu-shi Fukuoka, Japan, 806-8501National Hospital Organization Hokkaido Cancer Center | Sapporo Hokkaido, Japan, 003-0804Mito Medical Center | Higashiibaraki Ibaraki, Japan, 3113117Iwate Medical University Hospital | Shiwa-gun Yahaba-cho Iwate, Japan, 028-3695Shonan Kamakura General Hospital | Kamakura Kanagawa, Japan, 247-8533Saitama Medical University Hospital | Iruma Saitama, Japan, 350-0495Dokkyo Medical University Saitama Medical Center | Koshigaya Saitama, Japan, 343-0845Shizuoka Cancer Center | Nagaizumi-cho,Sunto-gun Shizuoka, Japan, 411-8777Nihon University Itabashi Hospital | Itabashiku Tokyo, Japan, 173-8610Chiba University Hospital | Chiba , Japan, 260-8677National Hospital Organization Kyushu Medical Center | Fukuoka , Japan, 810-8563Japanese Red Cross Fukuoka Hospital | Fukuoka , Japan, 815-8555Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital | Hiroshima , Japan, 730-0052Kumamoto University | Kumamoto , Japan, 860-8556The Japanese Red Cross Nagasaki Genbaku Hospital | Nagasaki , Japan, 852-8104The Jikei University Hospital | Tokyo , Japan, 105-8461Japanese Red Cross Medical Center | Tokyo , Japan, 150-8935Local Institution - 0335 | Tauranga Bay of Plenty, New Zealand, 3112Local Institution - 0340 | Dunedin Otago, New Zealand, 9016Local Institution - 0369 | Auckland , New Zealand, 1023Local Institution - 0334 | Auckland , New Zealand, 2025Local Institution - 0346 | Skórzewo Greater Poland Voivodeship, Poland, 60-185Local Institution - 0224 | Torun Kuyavian-Pomeranian Voivodeship, Poland, 87-100Local Institution - 0325 | Krakow Lesser Poland Voivodeship, Poland, 30-727Local Institution - 0250 | Warsaw Masovian Voivodeship, Poland, 02-776Local Institution - 0292 | Słupsk Pomeranian Voivodeship, Poland, 76-200Local Institution - 0185 | Katowice , Poland, 40-519Hospital de Braga | Braga , Portugal, 4710-243Champalimaud Foundation | Lisbon , Portugal, 1400-038Instituto Português de Oncologia do Porto Francisco Gentil, EPE | Porto , Portugal, 4200-072Local Institution - 0355 | San Juan , Puerto Rico, 00909Fundeni Clinical Institute | Bucharest , Romania, 022328Institutul Oncologic Cluj | Cluj-Napoca , Romania, 400124Institutul Regional de Oncologie Iasi | Iași , Romania, 700483Netcare Pretoria East Hospital | Centurion GP, South Africa, 0044Groote Schuur Hospital | Cape Town Western Cape, South Africa, 7925Haemalife | Kuilsriver Western Cape, South Africa, 7580Constantiaberg Haematology | Plumstead Western Cape, South Africa, 7800Local Institution - 0106 | Busan Busan, South Korea, 49241Pusan National University Hospital | Busan Busan, South Korea, 49241Local Institution - 0102 | Seongnam Gyeonggido, South Korea, 13620Seoul National University Bundang Hospital | Seongnam Gyeonggido, South Korea, 13620Chonnam National University Hwasun Hospital | Hwasun Jeonranamdo, South Korea, 58128Local Institution - 0103 | Hwasun Jeonranamdo, South Korea, 58128Local Institution - 0101 | Seoul Seoul Teugbyeolsi, South Korea, 03080Seoul National University Hospital | Seoul Seoul Teugbyeolsi, South Korea, 03080Samsung Medical Center | Seoul Seoul Teugbyeolsi, South Korea, 06351Local Institution - 0104 | Seoul Seoul Teugbyeolsi, South Korea, 06591The Catholic Univ. of Korea Seoul St. Mary's Hospital | Seoul Seoul Teugbyeolsi, South Korea, 06591Asan Medical Center | Seoul Seoul-teukbyeolsi [Seoul], South Korea, 05505Local Institution - 0105 | Seoul Seoul-teukbyeolsi, South Korea, 05505Local Institution - 0100 | Seoul , South Korea, 03722Severance Hospital, Yonsei University Health System | Seoul , South Korea, 03722Local Institution | Seoul , South Korea, 138-736Local Institution - 0183 | Palma Balearic Islands, Spain, 07120Hospital Universitari Son Espases | Palma Balears [Baleares], Spain, 07120Hospital Clínic de Barcelona | Barcelona Catalunya [Cataluña], Spain, 08036Local Institution - 0073 | Barcelona Catalunya [Cataluña], Spain, 08036Hospital General Universitario Morales Meseguer | Murcia Murcia, Región de, Spain, 30008Hospital Costa del Sol | Marbella Málaga, Spain, 29603Local Institution - 0182 | Marbella Málaga, Spain, 29603Hospital San Pedro de Alcantara | Cáceres , Spain, 10003Complejo Asistencial Universitario de León - Hospital de León | León , Spain, 24071Hospital Universitario 12 de Octubre | Madrid , Spain, 28041Local Institution - 0232 | Ankara , Turkey (Türkiye), 06620Local Institution - 0339 | Ankara , Turkey (Türkiye), 06680Local Institution - 0228 | Istanbul , Turkey (Türkiye), 34093Local Institution - 0229 | Izmir , Turkey (Türkiye), 35100Local Institution - 0226 | Kayseri , Turkey (Türkiye), 0Local Institution - 0227 | Samsun , Turkey (Türkiye), 55139Addenbrooke's Hospital | Cambridge Cambridgeshire, United Kingdom, CB2 0QQThe Royal Cornwall Hospital | Truro England, United Kingdom, TR1 3LJLanarkshire NHS Trust - Monklands Hospital | Airdrie Great Britain, United Kingdom, ML6 OJSKing's College Hospital | London Greater London, United Kingdom, SE5 9RSLeicester Royal Infirmary | Leicester Leicestershire, United Kingdom, LE1 5WWHammersmith Hospital | London London, City of, United Kingdom, W12 0HSBarnet Hospital | Barnet , United Kingdom, EN5 3DJFreeman Hospital | Newcastle upon Tyne , United Kingdom, NE7 7DNRoyal Stoke University Hospital | Stoke-on-Trent , United Kingdom, ST4 6QG
Investigators
Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb